To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Specialty chemical supplier Cognis receives GMP compliance for pharmaceutical excipients
First chemical company to obtain GMP compliance
17-07-2006: Cognis Germany recently became the first chemical company in the world to obtain GMP compliance for its pharmaceutical excipients. After successfully completing an audit carried out by the German Association for Certification of Quality Management Systems (DQS), the company's Düsseldorf site was certified GMP-compliant with no reservations. The certificate covers Nutrition & Health's PharmaLineTM product range.
Cognis' processes are based on the Good Manufacturing Practice (GMP) principles, and as such, they fulfill the standards of the International Pharmaceutical Excipients Council (IPEC). These include transparency in manufacturing processes, adherence to strict guidelines in the area of hygiene, and comprehensive documentation of production processes. The GMP Pharma standard sets even stricter benchmarks in the areas of training and hygiene, pest control, cleaning of production equipment, documentation of individual process steps, traceability of intermediate products and raw materials, and supplier auditing.
Certification leads to commercial opportunities
The audit procedure required the DQS to carry out a thorough inspection of Cognis' production facilities and laboratories, and the outcome of these was extremely positive. Cognis has successfully incorporated the GMP criteria into its own quality management system, for which it already has ISO 9001 and ISO 14001 certification. The audit report also praised the excellent standard of Cognis' production facilities. Comments Jochen Seifert, Global Product Line Manager, Pharmaceuticals & Healthcare: "GMP certification marks an important step forward in our efforts to market PharmaLineTM products internationally. It opens up new markets for us, and it also saves our customers from having to carry out some of their audits."
Watchlist
This is where you can add this news to your personal favourites
- 1Drew Industrial Division of Ashland Specialty Chemical Company purchases industrial water-treatment business of London-based Fer
- 2Allegra® Launched in Japan
- 3LG-DOW Polycarbonate Plant Starts Production in Korea to Effectively Meet Regional Needs
- 4Honeywell Appoints Terrence Hahn as Vice President and General Manager for Fluorine Products
- 5Caflon® surfactants from Univar as substitutes for banned nonylphenol ethoxylates
- 6Plurafac LF 303 - Plurafac LF 305: The new generation of low-foam surfactants
- 7Knoll AG: Pharma business sold for $6.9 billion:
- 8Putting electronic cigarettes to the test
- 9Not just cars, but living organisms need antifreeze to survive
- 10Stockhausen, a subsidiary of Degussa, develops a special product for de-inking and de-watering of sludge
